News
Current Report No. 1/2026 – Dates of publication of periodic reports in 2026
Legal basis: Article 52(2)(1) of the Act on Public Offering – current and periodic information. Acting pursuant to § 84(1) of the Regulation of the Minister of Finance of 6 June 2025 on current and periodic information disclosed by issuers of securities …, the Management Board of Celon Pharma S.A. (the “Issuer”) hereby announces theRead more »
Diamonds of Innovation 2025 for Celon Pharma
Celon Pharma has been named a laureate of the prestigious Diamonds of Innovation 2025 competition in the Pharmacy and Biotechnology category. The award was received by Krzysztof Dubiel, Director of Medicinal Chemistry at Celon Pharma, during the Executive Innovation Forum 2025 gala – an event that annually brings together leaders of innovation, business, and science.Read more »
Current report 18/2025 – Registration of an Amendment to the Company’s Articles of Association
Date of preparation: October 10, 2025 Legal basis: Article 56(1)(2) of the Act on Public Offering – current and periodic information Report content: The Management Board of Celon Pharma S.A. (the “Company”, the “Issuer”) hereby informs that on October 10, 2025, the District Court for the Capital City of Warsaw in Warsaw, 14th Commercial DivisionRead more »
Current Report No. 17/2025 – Execution of an Agreement by a Subsidiary with the General Contractor of the Investment Project,
Date: 3 October 2025, 17:07 Legal basis: Article 17(1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council (MAR) – inside information The Management Board of Celon Pharma S.A. (the “Company”, the “Issuer”) announces that on 3 October 2025 the Issuer’s subsidiary – Celon Pharma Slovakia s.r.o. (“Celon Pharma Slovakia”, theRead more »
Current report 16/2025 – Summary of Type B Meeting with the Food and Drug Administration (FDA) for CPL’36 in the treatment of schizophrenia
Legal basis: Art. 17 of the MAR Regulation – Inside information Report content: The Management Board of Celon Pharma S.A. (the “Company”, the “Issuer”) informs that on October 2, 2025, the Company received a summary of the Type B meeting held on October 1, 2025, containing responses to questions submitted for the combined pre-IND andRead more »
Current Report No. 14/2025 – Agreement with the European Bank for Reconstruction and Development on the principal terms of financing for a subsidiary in connection with project implementation
Subject: Agreement with the European Bank for Reconstruction and Development on the principal terms of financing for a subsidiary in connection with project implementationLegal basis: Article 17(1) of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation – MAR) – inside informationDateRead more »
Current Report No. 7/2025 – Execution of agreements on support for two Celon Pharma S.A. projects under the National Recovery and Resilience PlanLegal basis:
Subject: Execution of agreements on support for two Celon Pharma S.A. projects under the National Recovery and Resilience PlanLegal basis: Article 17(1) of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation – MAR) – inside informationDate and time of disclosure: 29Read more »
Current Report No. 8/2025 – Execution of agreement on support for a Celon Pharma S.A. project under the National Recovery and Resilience Plan
Subject: Execution of agreement on support for a Celon Pharma S.A. project under the National Recovery and Resilience PlanLegal basis: Article 17(1) of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation – MAR) – inside informationDate and time of disclosure: 6Read more »
CPL’36 Phase II clinical results to be presented at APA Annual Meeting
We’re excited to share that we’ll be presenting at the American Psychiatric Association (APA) Annual Meeting 2025, taking place May 17–21 in Los Angeles, California. Our team will showcase the Phase 2 clinical trial results of CPL’36, an innovative PDE10A inhibitor, in the treatment of acute exacerbations of schizophrenia. 📌 Poster session: May 18, 1:30–3:00Read more »
Current report 4/2025 – Phase II top – line results for CPL’ 36, a PDE10a inhibitor in the treatment of Dyskinesia in Parkinson’s disease
Legal basis Art. 17 section 1 MAR – confidential information. Report content: In reference to current report 17/2024 regarding positive results of the Phase II clinical trial on a drug based on CPL’36, an innovative PDE10A inhibitor, in the treatment of schizophrenia, in which the Company informed about the simultaneous ongoing Phase II clinical trialRead more »